Dostarlimab - GSK
Alternative Names: ANB 011; Dostarlimab-gxly; GSK-4057190; GSK-4057190A; JEMPERLI; Jemperli; TSR 042; WBP 285Latest Information Update: 28 Aug 2024
At a glance
- Originator AnaptysBio
- Developer GSK; Italian Sarcoma Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Endometrial cancer; Solid tumours
- Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Phase II/III Non-small cell lung cancer
- Phase II Breast cancer; Cervical cancer; Clear cell sarcoma; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Small cell lung cancer
Most Recent Events
- 23 Aug 2024 GlaxoSmithKline plans a phase II AZUR-4 trial for Adenocarcinoma (Neoadjuvant therapy, Late-stage disease, First line therapy, Combination therapy) in Belgium, Spain and United Kingdom in December 2024 (Parenteral) (NCT06567782)
- 02 Aug 2024 US FDA approves sNDA application for dostarlimab in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent)
- 02 Aug 2024 Efficacy and adverse events data from part 1 of phase III RUBY trial in Endometrial cancer released by GSK